Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMirallas Viñas, Oriol
dc.contributor.authorFilippi Arriaga, Maria Francesca Eugenia
dc.contributor.authorHernández Hernández, Irene
dc.contributor.authorAubanell, Anton
dc.contributor.authorChaachou, Anas
dc.contributor.authorGarcia-Alvarez, Alejandro
dc.contributor.authorHernando Cubero, Jorge
dc.contributor.authorMartinez Saez, Elena Antima
dc.contributor.authorBiagetti Biagetti, Betina
dc.contributor.authorCapdevila Castillon, Jaume
dc.date.accessioned2022-06-02T08:33:20Z
dc.date.available2022-06-02T08:33:20Z
dc.date.issued2021-11-11
dc.identifier.citationMirallas O, Filippi-Arriaga F, Hernandez Hernandez I, Aubanell A, Chaachou A, Garcia-Alvarez A, et al. Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report. Front Endocrinol. 2021 Nov 11;12:731631.
dc.identifier.issn1664-2392
dc.identifier.urihttp://hdl.handle.net/11351/7615
dc.descriptionAgressive pituitary tumors; Capecitabine; Temozolomide
dc.description.abstractNelson’s syndrome is considered a severe side effect that can occur after a total bilateral adrenalectomy in patients with Cushing’s disease. It usually presents with clinical manifestations of an enlarging pituitary tumor including visual and cranial nerve alterations, and if not treated, can cause death through local brain compression or invasion. The first therapeutic option is surgery but in extreme cases of inaccessible or resistant aggressive pituitary tumors; the off-label use of chemotherapy with capecitabine and temozolomide can be considered. However, the use of this treatment is controversial due to adverse events, lack of complete response, and inability to predict results. We present the case of a 48-year-old man diagnosed with Nelson’s syndrome with prolonged partial response and significant clinical benefit to treatment with capecitabine and temozolomide.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Endocrinology;12
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectAdenoma - Tractament
dc.subjectHipòfisi - Tumors - Tractament
dc.subjectQuimioteràpia combinada
dc.subject.meshNelson Syndrome
dc.subject.mesh/drug therapy
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshAdenoma
dc.titleAggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fendo.2021.731631
dc.subject.decssíndrome de Nelson
dc.subject.decs/farmacoterapia
dc.subject.decsprotocolos de quimioterapia antineoplásica combinada
dc.subject.decsadenoma
dc.relation.publishversionhttps://doi.org/10.3389/fendo.2021.731631
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Mirallas O, Garcia-Alvarez A, Hernando J, Capdevila J] Servei d’Oncologia Mèdica, Unitat de Tumors Gastrointestinals i Endocrins, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Filippi-Arriaga F] Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Hernandez Hernandez I, Biagetti B] Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Aubanell A] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Chaachou A, Martínez-Saez E] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid34858324
dc.identifier.wos000727887300001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record